Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk says diabetes drug candidate successful in phase III trials

Danish pharmaceutical company Novo Nordisk has revealed that its diabetes drug candidate liraglutide has shown positive results in two phase III clinical trials.

Danish pharmaceutical company Novo Nordisk has revealed that its diabetes drug candidate liraglutide has shown positive results in two phase III clinical trials.

The trials, which are the second and third in a series of five phase three studies in the group's ongoing LEAD programme, showed that the compound improved glucose control and lowered the body weight of the participants.

Liraglutide is a long-acting analogue of the naturally occurring hormone, Glucagon-Like Peptide-1 (GLP-1), which is rapidly broken down in the body and thus not practical as a therapy for type 2 diabetes. Studies to date show that liraglutide significantly improves glycaemic control in monotherapy and in combination therapy with metformin.

The trial results do not affect Novo Nordisk's previous financial expectations for 2007.

Novo Nordisk said it would post results from the remaining two LEAD studies in H2 2007 and Q1 2008.

Novo Nordisk's CSO, Mads Krogsgaard Thomsen, said of the data: "The encouraging clinical results from the two new trials confirm the positive effect of Liraglutide and leave us confident that we are on track to submit for regulatory approval mid-2008."

20th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics